A negative allosteric modulator for α5 subunit- containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in mice
Date
2017Journal
eNeuroPublisher
Society for NeuroscienceType
Article
Metadata
Show full item recordAbstract
New antidepressant pharmacotherapies that provide rapid relief of depressive symptoms are needed. The NMDA receptor antagonist ketamine exerts rapid antidepressant actions in depressed patients but also side effects that complicate its clinical utility. Ketamine promotes excitatory synaptic strength, likely by producing high-frequency correlated activity in mood-relevant regions of the forebrain. Negative allosteric modulators of GABA-A receptors containing α5 subunits (α5 GABA-NAMs) should also promote high-frequency correlated electroencephalogram (EEG) activity and should therefore exert rapid antidepressant responses. Because α5 subunits display a restricted expression in the forebrain, we predicted that α5 GABA-NAMs would produce activation of principle neurons but exert fewer side effects than ketamine. We tested this hypothesis in male mice and observed that the α5 GABA-NAM MRK-016 exerted an antidepressant-like response in the forced swim test at 1 and 24 h after administration and an anti-anhedonic response after chronic stress in the female urine sniffing test (FUST). Like ketamine, MRK-016 produced a transient increase in EEG γ power, and both the increase in γ power and its antidepressant effects in the forced swim test were blocked by prior administration of the AMPA-type glutamate receptor antagonist 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX). Unlike ketamine, however, MRK-016 produced no impairment of rota-rod performance, no reduction of prepulse inhibition (PPI), no conditioned-place preference (CPP), and no change in locomotion. α5 GABA-NAMs, thus reproduce the rapid antidepressant-like actions of ketamine, perhaps via an AMPA receptor (AMPAR)-dependent increase in coherent neuronal activity, but display fewer potential negative side effects. These compounds thus demonstrate promise as clinically useful fast-acting antidepressants. Copyright 2017 Zanos et al.Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029851700&doi=10.1523%2fENEURO.0285-16.2017&partnerID=40&md5=ac5a934ff1409ad04a0a11cc8bfbe971; http://hdl.handle.net/10713/10003ae974a485f413a2113503eed53cd6c53
10.1523/ENEURO.0285-16.2017
Scopus Count
Collections
Related articles
- Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABAA Receptors.
- Authors: Fischell J, Van Dyke AM, Kvarta MD, LeGates TA, Thompson SM
- Issue date: 2015 Oct
- Comparison of rapid and long-lasting antidepressant effects of negative modulators of α5-containing GABA<sub>A</sub> receptors and (R)‑ketamine in a chronic social defeat stress model.
- Authors: Xiong Z, Zhang K, Ishima T, Ren Q, Chang L, Chen J, Hashimoto K
- Issue date: 2018 Dec
- Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats.
- Authors: Koike H, Chaki S
- Issue date: 2014 Sep 1
- Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice.
- Authors: Nguyen L, Matsumoto RR
- Issue date: 2015 Dec 15
- Cortical and raphe GABA<sub>A</sub>, AMPA receptors and glial GLT-1 glutamate transporter contribute to the sustained antidepressant activity of ketamine.
- Authors: Pham TH, Defaix C, Nguyen TML, Mendez-David I, Tritschler L, David DJ, Gardier AM
- Issue date: 2020 May